Microcirculation in insulin resistance and diabetes: More than just a complication

Diabetes and Metabolism

Volumn 29, Issue 4 II, 2003, Pages

  Wiernsperger, N F ^a   Bouskela, E ^b  

^a Intl Pharmacological Support   (France)

^b STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Arteriolar vasomotion; Functional capillary density; Metformin; Microcirculation; Permeability

Indexed keywords

METFORMIN;

ARTERIOLE; BLOOD FLOW; CAPILLARY; CAPILLARY DENSITY; CAPILLARY PERMEABILITY; CELL ADHESION; DIABETES MELLITUS; ERYTHROCYTE; FLOW KINETICS; HUMAN; INSULIN RESISTANCE; LEUKOCYTE; METABOLISM; MICROANGIOPATHY; MICROCIRCULATION; MICROVASCULATURE; REVIEW; STIMULATION; VASCULAR DISEASE; VENULE;

EID: 18144441478     PISSN: 12623636     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1262-3636(03)72791-8     Document Type: Review

References (88)

1. Berg BR, Cohen KD, Sarelius IH. Direct coupling between blood flow and metabolism at the capillary level in striated muscle. Am J Physiol, 1997, 272, H2693-H2700.
2. Bunclgaard M. Functional implications of structural differences between consecutive segments of microvascular endothelium. Microcirc Endothelium Lymphatics, 1988, 4, 113-42.
3. Shimokawa H. The importance of the hyperpolarizing mechanism increases as the vessel size decreases in endothelium-dependent relaxations in rat mesenteric circulation. J Cardiovasc Pharmacol, 1996, 28, 703-11.
4. Pohl U, de Wit C. A unique role of NO in the control of blood flow. News Physiol Sci, 1999, 14, 74-80.
5. Frame MDS, Sarelius IH. Regulation of capillary perfusion by small arterioles is spatially organized. Circ Res, 1993, 73, 155-63.
6. Kollros PR, Konkle BA. Microvascular disease in diabetes mellitus. J Cardiovasc Risk, 1997, 4, 70-5.
7. Wiernsperger NE In defense of microvascular constriction in diabetes. Clin Hemorheol Microcirc, 2001, 25, 55-62.
8. Davis MJ. Myogenic response gradient in an arteriolar network. Am J Physiol, 1993, 264.H2168-H2179.
9. Schubert R, Mulvany MJ. The myogenic response: established facts and attractive hypotheses. Clin Sci, 1999, 96, 313-26.
10. Hassan AAK, Tooke JE. Mechanism of the postural vasoconstrictor response in the human foot. Clin Sci, 1988, 75, 379-87.
11. Rayman G, Williams SA, Gamble J, Tooke JE. A study of factors governing fluid filtration in the diabetic foot. Eur J Clin Invest, 1994, 24, 830-6.
12. Tooke JE. Microvascular function in human diabetes. A physiological perspective. Diabetes, 1995, 44, 721-6.
13. Belcaro G, Nicolaides AN. The venoarteriolar response in diabetics. Angiology, 1991, 42, 827-35.
14. Shore AC, Price KJ, Sandeman DD, Tripp JH, Tooke JE. Posturally induced vasoconstriction in diabetes mellitus. Arch Dis Child, 1994, 70, 22-6.
15. Yosipovitch G, Schneiderman J, Van Dyck DJ, Chetrit A, Milo G, Boner G. Impairment of the postural venoarteriolar response in young type 1 diabetic patients. A study by laser Doppler flowmetry. Angiology, 1996, 47, 687-91.
16. DeSanctis MT, Cesarone MR, Incandela L, Belcaro G, Acerbi G. Methods of evaluation and quantification of microangiopathy in high perfusion microangiopathy (chronic venous insufficiency and diabetic microangiopathy). J Cardiovasc Pharmacol Ther, 2002, 7 (suppl. 1), S3-S6.
17. Ubbink DT, Reneman RS, Jacobs MJHM. Effects of venous pressure and posture on skin capillary perfusion. Eur J Clin Invest, 1999, 29, 737-43.
18. Stern MP, Morales PA, Haffner SM, Valdez RA. Hyperdynamic circulation and the insulin resistance syndrome ("Syndrome X"). Hypertension, 1992, 20, 802-8.
19. Intaglietta M. Vasomotion and flowmotion: physiological mechanisms and clinical evidence. Vasc Med Rev, 1990, 1, 101-12.
20. Ellis CG, Wrigley SM, Groom AC. Heterogeneity of red blood cell perfusion in capillary network supplied by a single arteriole in resting skeletal muscle. Circ Res, 1994, 75, 357-68.
21. Sweeney TE, Sarelius IH. Arteriolar control of capillary cell flow in striated muscle. Circ Res, 1989, 64, 112-20.
22. Griffith TM, Edwards DH. Mechanisms underlying chaotic vasomotion in isolated resistance arteries: roles of calcium and EDRE. Biorheology, 1993, 30, 333-47.
23. Bartlett IS, Crane GJ, Neild TO, Segal SS. Electrophysiological basis of arteriolar vasomotion in vivo. J Vasc Res, 2000, 37, 568-75.
24. th International Symposium on Resistance Arteries, Muskoka Sands, 2001, 27.
25. Bertuglia S, Coppini G, Colantuoni A. Vasomotion in diabetic Syrian hamsters induced by metformin. In: Monduzzi eds. XIV Congresso Nazionale della Società Italiana di Microangiologia e Microcircolazione, Fírenze 7-9 dicembre 1989, 289-95.
26. Bouskela E. Effects of metformin on the wing circulation of normal and diabetic bats. Diabetes Metab, 1988, 14 (suppl. 4), 560-5.
27. Stansberry KB, Hill MA, Shapiro SA, McNitt PM, Bhatt BA, Vinik AI. Impairment of peripheral blood flow responses in diabetes resembles an enhanced aging effect. Diabetes Care, 1997, 20, 1711-6.
28. Renaudin C, Michoud E, Rapin JR, Lagarde M, Wiernsperger N. Hyperglycaemia modifies the reaction of microvessels to insu in rat skeletal muscle. Diabetologia, 1998, 41, 26-33.
29. Meyer MF, Rose CJ, Hulsmann JO, Schatz H, Pfohl M. Impaired 0.16 Hz vasomotion assessed by laser Doppler Anemometry as an early index of peripheral sympathetic neuropathy in diabetes. Microvasc Res, 2003, 65, 88-95.
30. Gniadecki R, Gniadecka M, Kotowski T, Serup J. Alterations of skin microcirculatory rhythmic oscillations in different positions of the lower extremity. Acta Dermatol Venereol, 1992, 72, 259-60.
31. Orija IB, Williams G, Benbow SJ. Impaired vasomotion and neurogenic vascular responses in the feb of NIDDM patients with neuropathy. Diabetic Med, 1998, 15 (suppl. 1), 564.
32. Rucker M, Strobel O, Vollmar B, Roesken F, Menger MD. Vasomotion in critically perfused muscle protects adjacent tissues from capillary perfusion failure. Am J Physiol Heart Circ Physiol, 2000, 279, H550-H558.
33. Katakam PVG, Ujhelyi MR, Hoenig M, Miller AW. Metformin improves vascular function in insulin-resistant rats. Hypertension, 2000, 35, 108-12.
34. Wiernsperger NF. Metformin: intrinsic vasculoprotective properties. Diabetes Technol Ther, 2000, 2, 259-72.
35. Vehkavaara S, Mäkimattila S, Schlenzka A, Vakkilainen J, Westerbacka J, Yki-Jarvinen H. Effect of 6 months of insulin therapy, acute hyperinsulinaemia and acute hyperglycaemia on endothelial function in type 2 diabetes. Diabetologia, 1999, 42 (suppl. 1), A224 [Abstract 841].
36. Mather KJ, Verma S, Anderson TJ. Improved endothelial function with Metformin in type 2 diabetes mellitus. J Am Coll Cardiol, 2001, 37, 1344-50.
37. Marfella R, Acampora R, Verrazzo G, et al. Metformin improves haemodynamic and theological responses to L-arginine in NIDDM patients. Diabetes Care, 1996, 19, 1-6.
38. Bouskela E, Wiernsperger N, Effects of metformin on haemorrhagic shock, blood volume, and ischemia/reperfusion on nondiabetic hamster. J Vasc Med Biol, 1993, 4, 41-6.
39. Bouskela E, Cyrino FZGA, Wiernsperger N. Effects of insulin and the combination of insulin plus metformin (Glucophage) on microvascular reactivity in control and diabetic hamsters. Angiology, 1997, 48, 503-14.
40. Bertuglia S, Coppini G, Colantuoni A. Effects of metformin on arteriolar vasomotion in normal and diabetic Syrian hamsters. Diabetes Metab, 1998, 14 (suppl. 4), 554-9.
41. 123iodine-labelled insulin in skeletal muscle of patients with type 2 diabetes. Effect of metformin. Diabetes Metab, 2002, 28, 95-103.
42. Valensi P, Behar A, André P, Wiernsperger N, Attali JR. The effects of metformin on the capillary permeability to albumin in women patients with cyclic aedema. Angiology, 1995, 46, 401-8.
43. Lutz TA, Estermann A, Haag S, Scharrer E. Depolarization of the liver cell membrane by metformin. Biochim Biophys Acta, 2001, 1513, 176-84.
44. Le Devehat C, Khodabandehlou T, Vimeux M. Impaired haemorheological properties in diabetic patients with lower limb arterial ischaemia. Clin Hemorheol Microcirc, 2001, 25, 43-8.
45. McHedlishvili G, Varazashvili M, Gobejishvili L. Local RBC aggregation disturbing blood fluidity and causing stasis in microvessels. Clin Hemorheol Microcirc, 2002, 26, 99-106.
46. Kindig CA, Sexton WL, Fedde MR, Poole DC. Skeletal muscle microcirculatory structure and haemodynamics in diabetes. Respir Physiol, 1998, 111, 163-75.
47. Rasio EA, Bendayan M. Sequential morphological and permeability changes in the rete capillaries during hyperglycaemia. Microsc Res Tech, 2002, 57, 408-17.
48. Beresewicz A, Czarnowska E, Maczewski M. Ischaemic preconditioning and superoxide dismutase protect against endothelial dysfunction and endothelium glycocalyx disruption in the Post-ischaemic guinea-pig hearts. Mol Cell Biochem, 1998, 186, 87-97.
49. Menger MD, Rücker M, Vollmar B. Capillary dysfunction in striated muscle ischemia/reperfusion: on the mechanisms of capillary " NO-Reflow". Shock, 1997, 8, 2-7.
50. Esposito K, Nappo F, Giugliano F, et al. Cytokine milieu tends toward inflammation in type 2 diabetes. Diabetes Care, 2003, 26, 1647-8.
51. Kunt T, Forst T, Harzer O, et al. The influence of advanced glycation endproducts (AGE) on the expression of human endothelial adhesion molecules. Exp Clin Endocrinol Diabetes, 1998, 106, 183-8.
52. Barnes AJ, Willars E], Clark PA, Hunt WB, Rampling M. Effects of metformin on haemcrheological indices in diabetes. Diabete Metab, 1988, 14, 608-9.
53. Kiesewetter H, Jung F, Gerhards M, Roggenkamp HG. Rheological effect of metformin on the blood of patients with dietetically controlled type 2b diabetes. Clin Hemorheol, 1987, 7, 781-91.
54. Rapin JR, Lespinasse P, Yoa R, Raymon L, Vaillant G, Brun JM. Effects of metformin on erythrocyte deformability in the presence of insulin. In vitro study on erythrocytes from diabetic patients. Diabete Metab, 1988, 14, 610-12,
55. Wiernsperger N. Membrane physiology as a basis for the cellular effects of metformin in insulin resistance and diabetes. Diabetes Metab, 1999, 25, 110-27.
56. Baron AD, Tarshoby M, Hook G, et al. Interaction between insulin sensitivity and muscle perfusion on glucose uptake in human skeletal muscle: evidence for capillary recruitment. Diabetes, 2000, 49, 768-74.
57. Rattigan S, Barrett LJ, Clark MG. Insulin-mediated capillary recruitment in skeletal muscle: this a mediator of insulin action on glucose metabolism? Curr Diab Rep, 2003, 3, 195-200.
58. th World Congress for Microcirculation, Sydney, Australia, 2001.
59. Ihlemann N, Stockholm KH, Eskildsent PC:. Impaired vascular reactivity is present despite normal levels of von Willebrand factor in patients with uncomplicated type 2 diabetes. Diabet Med, 2002, 19, 476-81.
60. Meyer MF, Schatz H. Influence of metabolic control and duration of disease on microvascular dysfunction in diabetes assessed by laser Doppler anemometry. Exp Clin Endocrinol Diabetes, 1998, 106, 395-403.
61. Bertuglia S, Colantuoni A, Donato L. Effects of metformin on microcirculation during haemorrhagic shock. In: Strano A, Novo S, eds. Advances in Vascular Pathology. Elsevier Science Publishers. Amterdam. 1989, pp 1189-1194.
62. Jansson L. Effects of the biguanide metformin on splanchnic blood flow in rats: preferential and dose-dependent increase in islet blood flow. Pharmacology, 1995, 51, 43-7.
63. Jansson PAE, Gucbjörnsdóttir HS, Andersson OK, Lönnroth PN. The effect of metformin on adipose tissue metabolism and peripheral blood flow in subjects with NIDDM. Diabetes Care, 1996, 19, 160-4.
64. Jakubowicz DJ, Seppälä M, Jakubowicz S, et al. Insulin reduction with metformin increases luteal phase serum glycodelin and insulin-like growth factor-binding protein 1 concentrations and enhances uterine vascularity and blood flow in the polycystic ovary syndrome. J Clin Endocrinol Metab, 2001, 86, 1126-33.
65. Kelly JJ, Pham H, Martin A, Whitworth JA. Metabolic and haemodynamic effects of short term metformin administration in normotensive men. Am J Hypertension, 1995, 8, G15.
66. Sirtori CR, Franceschini G, Gianfranceschi G, et al. Metformin improves peripheral vascular flow in nonhyperlipidaemic patients with arterial disease. J Cardiovasc Pharmacol, 1984, 6, 914-923.
67. Tedgui A. Endothelial permeability under physiological and pathological conditions. Prostaglandins, Leukot Essent Fatty Acids, 1996, 54, 27-9.
68. Svensjo E, Cyrino F, Michoud E, Ruggiero D, Bouskela E, Wiernsperger N. Vascular permeability increase as induced by histamine or bradykinin is enhanced by advanced glycation endproducts (AGEs). J Diabetes Complic, 1999, 13, 187-90.
69. Viberti GC. Increased capillary permeability in diabetes mellitus and its relationship to microvascular angiopathy. Am J Med, 1983, 75, 81-4.
70. Colantuoni A, Bertuglia S, Donato L. Effects of metformin on microvascular permeability in diabetic syrian hamsters. Diabete Metab, 1988, 14 (suppl.), 549-53.
71. Campbell IW, Menzies DG, McBain AM, Brown IR. Effects of metformin on blood pressure and microalbuminuria in diabetes mellitus. Diabete Metab, 1988, 14 (suppl.), 613-7.
72. Jaap AJ, Tooke JE. Pathophysiology of microvascular disease in non-insulin-dependent diabetes. Clin Sci, 1995, 89, 3-12.
73. UK Prospective Diabetes Study Group 34. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet, 1998, 352, 854-65.
74. Reichard P, Nilsson BY, Rosenquist U. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med, 1993, 329, 304-9.
75. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med, 1993, 329, 977-86.
76. Verotti A, Trotta D, Salladini C, Laura M, Chiarelli F. Preventing microvascular diabetic complications in children and adolescents: looking beyond glycaemic control. Expert Opin Pharmacother, 2003, 4,525-32.
77. Yu Y, Ohmori K, Kondo I, et al. Correlation of functional and strucrural alterations of the coronary arterioles during development of type II diabetes mellitus in rats. Cardiovasc Res, 2002, 56, 303-11.
78. Brun JF, Fons C, Supparo I, Mallard C, Orsetti A. Relationships between metabolic and hemorheologic modifications associated with overweight. Clin Hemorheol, 1993, 13, 201-13.
79. Rottiche CE, Lima JAC, Bluemke DA, et al. Magnitude and time course of microvascular obstruction and tissue injury after acute myocardial infarction. Circulation, 1998, 98, 1006-14.
80. DeFily DV. Control of microvascular resistance in physiological conditions and reperfusion. J Mol Cell Cardiol, 1998, 30, 2547-54.
81. Gavin JB, Maxwell L, Edgar SG. Microvascular involvement in cardiac pathology. J Mol Cell Cardiol, 1998, 30, 2531-40.
82. Baron AD. Insulin resistance and vascular function. J Diabetes Complic, 2002, 16, 92-102.
83. Wiernsperger N. Defects in microvascular haemodynamics during prediabetes contributor or epiphenomenon? Diabetologia, 2000, 43, 1439-48.
84. Tooke JE, Hannemann MM. Adverse endothelial function and the insulin resistance syndrome. J Intern Med, 2000, 247, 425-31.
85. Clark MG, Wallis MG, Barrett EJ, et al. Blood flow and muscle metabolism: a focus on insulin action. Am J Physiol, 2003, 284, E241-E258.
86. Caballero AE, Arora S, Saouaf R, et al. Microvascular and macrovascular reactivity is reduced in subjects at risk for type 2 diabetes. Diabetes, 1999, 48, 1856-62.
87. Irving RJ, Walker BR, Noon JP, Watt GC, Webb DJ, Shore AC. Microvascular correlates of blood pressure, plasma glucose, an insulin resistance in health. Cardiovasc Res, 2002, 53, 271-6.
88. Tooke JE, Goh KL. Endotheliopathy precedes type 2 diabetes, Diabetes Care, 1998, 21, 2047-9.